• Users Online: 480
  • Print this page
  • Email this page
Year : 2021  |  Volume : 59  |  Issue : 1  |  Page : 56-60

Rho-kinase inhibitors in ophthalmology

Department of Glaucoma, Glaucoma Services, Aravind Eye Hospital, Puducherry, India

Correspondence Address:
Dr. Srinivasan Kavitha
Glaucoma Services, Aravind Eye Hospital, Puducherry
Login to access the Email id

Source of Support: None, Conflict of Interest: None

DOI: 10.4103/tjosr.tjosr_146_20

Get Permissions

Rho-kinase (ROCK) inhibitor is the newer drug available for glaucoma in the Indian market. It seems to target the actual area of disease pathology which has not been the case with the available medications. With the ever-evolving potential of these drugs in various diseases in ophthalmology, it would be wise to know about them. This review article aims to provide information regarding the role of ROCK and its inhibitors in glaucoma, corneal diseases, and retinal pathologies. A thorough search of several databases was conducted with ROCK inhibitors being one of the main keywords.

Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)

 Article Access Statistics
    PDF Downloaded24    
    Comments [Add]    

Recommend this journal